Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91148 | 0.85 | S1PR4 (0.55) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31651666 | 0.84 | S1PR4 (0.50) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2842190 | 0.83 | S1PR4 (0.54) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4155091 | 0.81 | S1PR4 (0.55) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4158695 | 0.79 | S1PR4 (0.54) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31362449 | 0.79 | S1PR4 (0.58) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL25100353 | 0.79 | S1PR4 (0.54) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19687644 | 0.79 | S1PR4 (0.54) | S1PR4LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12031808 | 0.77 | CHRNB2 (0.46) | LMNASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL1758844 | 0.77 | RAB9A (0.37) | S1PR4LMNASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | S1PR4 307/4885LMNA 4446/4885SMN1; SMN2 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.